1. Home
  2. SOWG vs MNOV Comparison

SOWG vs MNOV Comparison

Compare SOWG & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sow Good Inc.

SOWG

Sow Good Inc.

HOLD

Current Price

$2.99

Market Cap

63.4M

ML Signal

HOLD

Logo Medicinova Inc

MNOV

Medicinova Inc

N/A

Current Price

$1.34

Market Cap

67.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SOWG
MNOV
Founded
2010
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.4M
67.9M
IPO Year
2011
2004

Fundamental Metrics

Financial Performance
Metric
SOWG
MNOV
Price
$2.99
$1.34
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.50
AVG Volume (30 Days)
17.2K
37.0K
Earning Date
05-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,360,807.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$180.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
194.15
52 Week Low
$0.10
$1.17
52 Week High
$4.45
$1.96

Technical Indicators

Market Signals
Indicator
SOWG
MNOV
Relative Strength Index (RSI) 44.31 47.47
Support Level $0.38 $1.30
Resistance Level $4.43 $1.46
Average True Range (ATR) 0.27 0.04
MACD -0.12 -0.00
Stochastic Oscillator 23.04 33.33

Price Performance

Historical Comparison
SOWG
MNOV

About SOWG Sow Good Inc.

Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats. The company operates in one reportable segment, reflecting its capital-light business model under which it earns proceeds from the sale of freeze-dried candy products.

About MNOV Medicinova Inc

MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

Share on Social Networks: